1. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype 
Romain Micol, MD, MPH, PhD, Lilia Ben Slama, PhD, Felipe Suarez, MD, PhD, Loïc Le Mignot, MSc, Julien Beauté, MD, MSc, Nizar Mahlaoui, MD, MSc, Catherine Dubois d’Enghien, BSc, Anthony Laugé, BSc, Janet Hall, PhD, Jérôme Couturier, MD, Louis Vallée, MD, Bruno Delobel, MD, François Rivier, MD, PhD, Karine Nguyen, MD, Thierry Billette de Villemeur, MD, Jean-Louis Stephan, MD, Pierre Bordigoni, MD, Yves Bertrand, MD, Nathalie Aladjidi, MD, Jean-Michel Pedespan, MD, Caroline Thomas, MD, Isabelle Pellier, MD, MSc, Michel Koenig, MD, PhD, Olivier Hermine, MD, PhD, Capucine Picard, MD, PhD, Despina Moshous, MD, PhD, Bénédicte Neven, MD, PhD, Fanny Lanternier, MD, Stéphane Blanche, MD, Marc Tardieu, MD, PhD, Marianne Debré, MD, Alain Fischer, MD, PhD, Dominique Stoppa-Lyonnet, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 128, Issue 2, Pages e1 (August 2011)
DOI: /j.jaci
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Life expectancy of patients with A-T based on ATM mutation. A, Survival in 102 patients in group 0 (biallelic null mutations, red curve) and 74 patients in group 1 (≥1 hypomorphic mutation, black curve; P = .3, log-rank test). The Kaplan-Meier 20-year survival rates were 54.7% for patients in group 0 and 64.1% for patients in group 1. B, Onset of cancer in groups 0 and 1 (P = .01, log-rank test). The mean age at onset of cancer was 11.8 ± 6.4 years in group 0 and 20.2 ± 13.2 years in group 1.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig E1
Survival of 240 patients with A-T. As a function of the year of birth (P = .3, log-rank test), the Kaplan-Meier 20-year survival rate was 58.9%.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions